Shire's oncology business includes in-market products ONCASPAR® (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL) and ex-U.S. and ex-Taiwan rights to ONIVYDE® (irinotecan pegylated liposomal formulation), a component of multi-agent treatment for metastatic pancreatic cancer post gemcitabine-based therapy. The portfolio also includes Calaspargase Pegol (Cal-PEG), which is under FDA review for the treatment of ALL and early stage immuno-oncology pipeline collaborations.
A Hogan Lovells team consisting of lawyers from 13 of Hogan Lovells global offices, helped with closing ex-US portions of the multi-jurisdictional stock and asset sale.
The team was led by New York and Washington D.C. M&A partners Adam Golden and Mahvesh Qureshi along with senior associate Steven Palyca, and associates Kelsey Moran and Kathleen Blanchard.
From the UK, of counsel Penny Powell, senior associate George Jenkins and M&A Partner Tom Brassington advised. In France, the team consisted of Corporate partners Mikael Salmela and Xavier Doumen, and associate Andrea Segura. In Spain, partner Alex Dolmans and senior associate Adrián Fernández de Pedro advised. In Germany, Hamburg partner Arne Thiermann and Dusseldorf partner Birgit Reese advised on regulatory and corporate aspects of the transaction. In the Netherlands, of counsel Peter Stokking advised on corporate matters. In Poland, partner Marek Wroniak and counsel Tomasz Żak also advised on corporate aspects. In Italy, M&A partner Francesco Stella, senior associate Pierluigi Feliciani, senior associate Martina di Nicola, and counsel Riccardo Fruscalzo advised on corporate and regulatory matters; along with Tax partner Fulvia Astolfi and senior associate Maria Cristina Conte. Singapore partner Stephanie Keen and senior associate Ally Smith provided M&A advice. Mexico partner Guillermo Gonzalez, Brazilian partner Isabel da Costa Carvalho and senior associate Rafael Szmid provided corporate advice.